Novavax, Inc. (NVAX) — closed signal from March 10, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 8, 2026.
Predicted vs. what happened
What happened
Reached 58% of the predicted growth at its peak, without hitting the target.
The thesis — published March 10, 2026
Novavax now shows real business improvement: it unexpectedly made money recently and signed a licensing deal with Pfizer. Those facts give a believable path for the stock to be valued higher soon. The biggest danger is unpredictable biotech news, but this recovery looks grounded in operations, not just hype.
Primary drivers
- Unexpected profit makes the near-term business story stronger
- Pfizer deal gives validation and possible steady revenue
- Price trend is getting healthier but not yet overly stretched
- Protein vaccine tech can support multiple commercial products
How it played out
NVAX: the target was not reached
Lyra published NVAX at $10.51 on 2026-03-10 with 18% expected growth and a $12.40 target. The thesis pointed to an unexpected profit, a Pfizer licensing deal, a healthier price trend, and protein vaccine technology that could support multiple commercial products.
Inside the window, NVAX rose but did not reach the target. The peak was $11.61 on 2026-05-27, a 10.4% gain. It never got there. By 2026-06-08, the stock ended at $8.62. The thesis partially played out on the early move, then missed the target and finished below the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.